OBJECTIVE: To examine whether genetic polymorphisms in the cholesteryl-ester transfer protein (CETP) and the P-glycoprotein drug transporter (MDR1), are associated with variable lipid response to fluvastatin. METHODS:Lipid levels were determined in a compliance-monitored clinical study at baseline and following 20 weeks of treatment with 40 mg dose of fluvastatin in 76 FH patients. CETP and MDR1 SNP genotyping was performed and linear regression was used to examine the associations between common SNPs and haplotypes and lipid response. RESULTS: Treatment with 40 mg of fluvastatin resulted in mean low density lipoprotein cholesterol (LDL-C) reduction of 21.5%; mean triglyceride (TG) reduction of 8.3%; and a mean high-density lipoprotein cholesterol (HDL-C) increase of 13.4%. Five tagging SNPs in both genes were used to reconstruct five and six haplotypes accounting for 71.4% and 90.2% of the observed haplotypes in the CETP and MDR1 genes, respectively. CETP-H13 and MDR1-h4 were associated with an increase in LDL-C response. CETP-H5 was significantly associated with decreased TG and HDL-C response, whereas MDR1-h10 was associated with decreased TG response. A multivariate regression model indicated an independent additive effect of CETP-H5 and MDR1-h10 on the level of TG response. CONCLUSIONS: CETP and MDR1 have independent effects on lipid changes following fluvastatin treatment. The results of this study may lead to an improved understanding of the genetic determinants of lipids response to treatment.
RCT Entities:
OBJECTIVE: To examine whether genetic polymorphisms in the cholesteryl-ester transfer protein (CETP) and the P-glycoprotein drug transporter (MDR1), are associated with variable lipid response to fluvastatin. METHODS:Lipid levels were determined in a compliance-monitored clinical study at baseline and following 20 weeks of treatment with 40 mg dose of fluvastatin in 76 FHpatients. CETP and MDR1 SNP genotyping was performed and linear regression was used to examine the associations between common SNPs and haplotypes and lipid response. RESULTS: Treatment with 40 mg of fluvastatin resulted in mean low density lipoprotein cholesterol (LDL-C) reduction of 21.5%; mean triglyceride (TG) reduction of 8.3%; and a mean high-density lipoprotein cholesterol (HDL-C) increase of 13.4%. Five tagging SNPs in both genes were used to reconstruct five and six haplotypes accounting for 71.4% and 90.2% of the observed haplotypes in the CETP and MDR1 genes, respectively. CETP-H13 and MDR1-h4 were associated with an increase in LDL-C response. CETP-H5 was significantly associated with decreased TG and HDL-C response, whereas MDR1-h10 was associated with decreased TG response. A multivariate regression model indicated an independent additive effect of CETP-H5 and MDR1-h10 on the level of TG response. CONCLUSIONS:CETP and MDR1 have independent effects on lipid changes following fluvastatin treatment. The results of this study may lead to an improved understanding of the genetic determinants of lipids response to treatment.
Authors: Jenni E Keskitalo; Kaisa J Kurkinen; Mikko Neuvonen; Janne T Backman; Pertti J Neuvonen; Mikko Niemi Journal: Br J Clin Pharmacol Date: 2009-08 Impact factor: 4.335
Authors: Candace M Kammerer; David L Rainwater; Nicolas Gouin; Madhuri Jasti; Kory C Douglas; Amy S Dressen; Prasanth Ganta; John L Vandeberg; Paul B Samollow Journal: J Lipid Res Date: 2010-07-22 Impact factor: 5.922
Authors: Wai-Johnn Sam; Christine E Chamberlain; Su-Jun Lee; Joyce A Goldstein; Douglas A Hale; Roslyn B Mannon; Allan D Kirk; Yuen Yi Hon Journal: Transplantation Date: 2012-11-15 Impact factor: 4.939
Authors: Marco Ferrari; Luigina Guasti; Andrea Maresca; Mauro Mirabile; Sara Contini; Anna Maria Grandi; Franca Marino; Marco Cosentino Journal: Eur J Clin Pharmacol Date: 2014-03-06 Impact factor: 2.953
Authors: Iris Postmus; Helen R Warren; Stella Trompet; Benoit J Arsenault; Christy L Avery; Joshua C Bis; Daniel I Chasman; Catherine E de Keyser; Harshal A Deshmukh; Daniel S Evans; QiPing Feng; Xiaohui Li; Roelof A J Smit; Albert V Smith; Fangui Sun; Kent D Taylor; Alice M Arnold; Michael R Barnes; Bryan J Barratt; John Betteridge; S Matthijs Boekholdt; Eric Boerwinkle; Brendan M Buckley; Y-D Ida Chen; Anton J M de Craen; Steven R Cummings; Joshua C Denny; Marie Pierre Dubé; Paul N Durrington; Gudny Eiriksdottir; Ian Ford; Xiuqing Guo; Tamara B Harris; Susan R Heckbert; Albert Hofman; G Kees Hovingh; John J P Kastelein; Leonore J Launer; Ching-Ti Liu; Yongmei Liu; Thomas Lumley; Paul M McKeigue; Patricia B Munroe; Andrew Neil; Deborah A Nickerson; Fredrik Nyberg; Eoin O'Brien; Christopher J O'Donnell; Wendy Post; Neil Poulter; Ramachandran S Vasan; Kenneth Rice; Stephen S Rich; Fernando Rivadeneira; Naveed Sattar; Peter Sever; Sue Shaw-Hawkins; Denis C Shields; P Eline Slagboom; Nicholas L Smith; Joshua D Smith; Nona Sotoodehnia; Alice Stanton; David J Stott; Bruno H Stricker; Til Stürmer; André G Uitterlinden; Wei-Qi Wei; Rudi G J Westendorp; Eric A Whitsel; Kerri L Wiggins; Russell A Wilke; Christie M Ballantyne; Helen M Colhoun; L Adrienne Cupples; Oscar H Franco; Vilmundur Gudnason; Graham Hitman; Colin N A Palmer; Bruce M Psaty; Paul M Ridker; Jeanette M Stafford; Charles M Stein; Jean-Claude Tardif; Mark J Caulfield; J Wouter Jukema; Jerome I Rotter; Ronald M Krauss Journal: J Med Genet Date: 2016-09-01 Impact factor: 6.318